Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 10
Opinion
Video
Combinations and Treatment Sequence Strategies in Breast Cancer
In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.
- ELECTRA (Elacestrant + abemaciclib)
Related Videos
Related Content
